Danaher Confirms Third Quarter and Full Year 2024 Guidance
Danaher (NYSE: DHR) has reaffirmed its previously issued guidance for the third quarter and full year 2024. The company expects non-GAAP core revenue to decline by low-single digits year-over-year for both periods. This confirmation comes ahead of a scheduled analyst event on September 5, 2024, in Washington, D.C., hosted by Julie Sawyer Montgomery, Executive Vice President of Diagnostics.
Danaher provides forecasts only on a non-GAAP core revenue basis due to difficulties in estimating other GAAP revenue components such as currency translation, acquisitions, and divested product lines. The analyst meeting will be webcast on Danaher's website, with a replay available after the presentation.
Danaher (NYSE: DHR) ha confermato le previsioni precedentemente emesse per il terzo trimestre e l'intero anno 2024. L'azienda prevede che i ricavi core non-GAAP diminuiranno di una bassa cifra singola anno su anno per entrambi i periodi. Questa conferma arriva in vista di un evento per analisti programmato il 5 settembre 2024 a Washington, D.C., ospitato da Julie Sawyer Montgomery, Vicepresidente Esecutivo di Diagnostica.
Danaher fornisce previsioni solo su base di ricavi core non-GAAP a causa delle difficoltà nel calcolo di altri componenti dei ricavi GAAP, come la traduzione valutaria, le acquisizioni e le linee di prodotto dismesse. La riunione con gli analisti sarà trasmessa in diretta sul sito web di Danaher, con una registrazione disponibile dopo la presentazione.
Danaher (NYSE: DHR) ha reafirmado su guía previamente emitida para el tercer trimestre y el año completo 2024. La compañía espera que los ingresos centrales no-GAAP disminuyan en cifras bajas de un solo dígito año tras año para ambos períodos. Esta confirmación llega antes de un evento programado para analistas el 5 de septiembre de 2024 en Washington, D.C., organizado por Julie Sawyer Montgomery, Vicepresidenta Ejecutiva de Diagnósticos.
Danaher proporciona pronósticos únicamente en base a ingresos centrales no-GAAP debido a las dificultades para estimar otros componentes de ingresos GAAP, como la traducción de divisas, adquisiciones y líneas de productos desinvertidos. La reunión con los analistas será transmitida en vivo en el sitio web de Danaher, con una repetición disponible después de la presentación.
다나허 (NYSE: DHR)는 2024년 3분기 및 전체 연도에 대한 기존 가이던스를 재확인했습니다. 회사는 비-GAAP 핵심 수익이 전년 대비 낮은 한 자릿수 감소할 것이라고 예상합니다 두 기간 모두. 이 확인은 2024년 9월 5일 워싱턴 D.C.에서 열릴 예정인 분석가 이벤트를 앞두고 이루어졌으며, 주최자는 진단 부서의 부사장 줄리 소여 몽고메리입니다.
다나허는 환율 변동, 인수 및 매각된 제품 라인 등의 다른 GAAP 수익 구성 요소를 추정하는 데 어려움이 있기 때문에 비-GAAP 핵심 수익 기준으로만 예측을 제공합니다. 애널리스트 회의는 다나허 웹사이트에서 생중계되며, 발표 후 다시 볼 수 있는 재생 기능이 제공됩니다.
Danaher (NYSE: DHR) a réaffirmé ses prévisions précédemment émises pour le troisième trimestre et l'ensemble de l'année 2024. L'entreprise s'attend à ce que les revenus principaux non-GAAP diminuent de faibles chiffres à un chiffre d'une année sur l'autre pour les deux périodes. Cette confirmation intervient avant un événement prévu pour les analystes le 5 septembre 2024 à Washington, D.C., animé par Julie Sawyer Montgomery, Vice-Présidente Exécutive des Diagnostics.
Danaher ne fournit des prévisions que sur la base de revenus principaux non-GAAP en raison des difficultés à estimer d'autres components de revenus GAAP comme la conversion monétaire, les acquisitions et les lignes de produits cédées. La réunion des analystes sera diffusée en direct sur le site Web de Danaher, avec une rediffusion disponible après la présentation.
Danaher (NYSE: DHR) hat seine zuvor veröffentlichten Prognosen für das dritte Quartal und das gesamte Jahr 2024 bekräftigt. Das Unternehmen erwartet, dass der non-GAAP-Kernerlös im Vergleich zum Vorjahr um niedrige einstellige Ziffern zurückgehen wird für beide Zeiträume. Diese Bestätigung erfolgt im Vorfeld einer geplanten Analystenveranstaltung am 5. September 2024 in Washington, D.C., die von Julie Sawyer Montgomery, Executive Vice President Diagnostics, geleitet wird.
Danaher gibt nur Prognosen auf Basis des non-GAAP-Kernerlöses ab, da es Schwierigkeiten hat, andere GAAP-Umsatzkomponenten wie Währungsumrechnungen, Übernahmen und ausgegliederte Produktlinien abzuschätzen. Das Analystentreffen wird live auf der Website von Danaher übertragen, mit einer Wiederholung, die nach der Präsentation verfügbar ist.
- Reaffirmation of previously issued guidance, indicating stability in financial outlook
- Transparency in providing forward-looking financial information to investors
- Scheduled analyst meeting, demonstrating commitment to investor communication
- Projected decline in non-GAAP core revenue for both Q3 and full year 2024
- guidance provided, focusing only on non-GAAP core revenue
Danaher's reaffirmation of its guidance suggests stability in their financial outlook, but the projected low-single digit decline in non-GAAP core revenue for both Q3 and full-year 2024 raises concerns. This guidance implies continued market challenges across Danaher's diverse portfolio of businesses.
The company's reliance on non-GAAP metrics for forecasting, while common, makes it challenging to gauge the full financial picture. Investors should note that this excludes currency fluctuations, acquisitions and divestitures, which could significantly impact actual GAAP results.
The upcoming analyst meeting may provide important insights into Danaher's strategies to navigate this anticipated revenue decline and maintain profitability. Investors should pay close attention to any discussions on cost-cutting measures, innovation pipelines, or market expansion plans that could offset the projected revenue weakness.
Danaher's guidance suggests a broader slowdown in the life sciences and diagnostics sectors, which are key markets for the company. The projected revenue decline could indicate reduced demand for research tools, diagnostic equipment and related consumables.
This trend might be influenced by factors such as reduced healthcare spending, budget constraints in academic research, or a normalization of demand following the pandemic-driven surge. Competitors in these spaces may face similar headwinds, potentially signaling a sector-wide challenge rather than a company-specific issue.
Investors should monitor peer companies' performance and industry reports to contextualize Danaher's outlook. The analyst meeting may shed light on specific product lines or geographic regions driving the slowdown, providing valuable insights for assessing the company's competitive position and growth prospects.
The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other components of GAAP revenue, such as currency translation, acquisitions and divested product lines. For both the third quarter and full year 2024, the Company continues to expect that non-GAAP core revenue will be down low-single digits year-over-year.
As previously announced, Danaher will hold an analyst meeting in
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the third quarter and full year 2024 and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: unanticipated, further declines in demand for our COVID-19 related products, the impact of global health crises, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of
View original content:https://www.prnewswire.com/news-releases/danaher-confirms-third-quarter-and-full-year-2024-guidance-302238099.html
SOURCE Danaher Corporation
FAQ
What is Danaher's revenue guidance for Q3 and full year 2024?
Why does Danaher only provide non-GAAP core revenue guidance?
When and where is Danaher's upcoming analyst meeting?
Who will host Danaher's September 2024 analyst meeting?
